Fountain presents menopause hormone care as a complete program, with a personalized kit and several ways to pay for access. That packaging can make the offer easy to recognize while leaving the medicine itself surprisingly difficult to identify. A program containing hormone treatment is not necessarily an offer for one specified progesterone capsule.
We reviewed Fountain’s hormone-care page and published terms on September 29, 2026. This is an assessment of the service, its purchase descriptions and the questions surrounding a possible prescription. It does not establish which medicine a clinician would recommend or what a pharmacy would dispense to a particular patient.
In this article
The clinical offer is broader than a capsule listing
The hormone-care page describes clinician-led menopause treatment and discusses progesterone as part of hormone care. It also advertises a personalized Hormone Therapy Kit. Those records establish a relevant clinical service, but they do not identify an oral progesterone manufacturer, capsule formulation or complete ingredient declaration.
The kit should therefore be unpacked in words before its contents are compared with another medicine. Which items would be prescribed, which would serve a different purpose, and which are merely possible options? The medicine-purpose guide helps distinguish that clinical explanation from the program’s marketing name. A reader should not have to infer an oral route from a general reference to hormone replacement.
A named hormone still leaves product status unresolved
Fountain’s terms describe medical services provided through independently owned medical groups and make prescribing subject to professional judgment. A membership or paid consultation does not itself establish a prescription. Nor does the public service description establish whether a proposed preparation would be an approved product or a compounded medicine.
The FDA’s explanation of compounded drugs says those drugs are not FDA approved. That distinction should be applied to an identified preparation, not assigned to every Fountain treatment without evidence. Lifeforce’s review examines a different example in which a product name and allergy notice are published but several identity questions remain. Both services require more specificity than a hormone-category label supplies.
An ingredient question belongs to the actual dispensed item
Nothing in the reviewed kit description provides a complete excipient list for a particular progesterone capsule. A personalized service is not evidence that its medicine is free of an ingredient someone needs to avoid. The capsule-excipient guide explains why a product name, pharmacy label and current ingredient information belong together.
For a concrete contrast, the FDA Prometrium label names peanut oil and gelatin and contraindicates that product in patients allergic to peanuts. Fountain’s pages do not establish that it supplies Prometrium. The useful question is which ingredient information applies to the proposed item, including any formulation-specific uncertainty, rather than whether a hormone program sounds natural or customized.
The payment periods are four, twelve and forty-eight weeks
The current plan cards display Starter at $199 per four weeks, with $199 billed every four weeks. Standard displays $167 per four weeks alongside a $499 total billed every twelve weeks. Pro displays $150 per four weeks alongside $1,799 billed every forty-eight weeks. The total and billing interval are the purchase records; the shorter-period displays are not separate installment promises.
These periods should not be relabeled calendar months or an ordinary calendar year. The displayed equivalents also should not replace the stated totals with a recalculated charge. Newson Clinic’s UK review offers a useful contrast with separately priced appointments. Different billing structures can be compared only after the included clinical work and medicines have been identified.
Pharmacy choice does not settle what the bundle pays for
The published terms, dated April 3, 2024, state that a valid prescription may be filled at a pharmacy of the patient’s choice. That is a meaningful distinction from assuming a kit can only come through one dispensing route. It does not establish that an outside pharmacy’s charge is included in the advertised bundle or reimbursed by Fountain.
The page’s all-inclusive language needs a written explanation tied to the selected arrangement: which medicines, tests and services are included, and which costs arise elsewhere? The subscription terms say subscriptions renew automatically unless the patient contacts Fountain to cancel before the current period ends; the account then closes at that period’s end. Those published rules do not settle an individual refund outcome or every selected-agreement detail. This review has not tested a purchase or a request to use another pharmacy.
Delivery and support promises are different from clinical timing
The program page advertises rapid shipping and around-the-clock support. Those statements do not establish when a consultation, prescribing decision or symptom assessment would occur. Shipping a kit is also not evidence that every item has an identical role or that an unwanted effect can wait for routine messaging.
The terms expressly separate the service from emergency care. For medication questions, the follow-up guide focuses on who can assess the concern and how the patient reaches that person. For the exact Prometrium product, the FDA label warns of dizziness and drowsiness. That product-specific caution supports asking about practical effects of the actual prescription, without supplying a timing plan for Fountain’s unidentified medicine.
A useful consultation would turn the kit into a clear proposal
Fountain’s clinical offer is relevant to someone seeking a menopause-care assessment. Its value for an oral-progesterone comparison depends on the details that follow: the intended purpose, exact preparation, route, ingredient record, dispensing arrangement and responsibility for follow-up. Those details should make the proposed care understandable without requiring a reader to decode a bundle.
The remaining financial question is equally specific: what does the selected billing commitment purchase, and what remains payable elsewhere? An attractive period equivalent cannot answer that. Fountain belongs in a clinical-service comparison, but the reviewed pages do not justify describing an unconfirmed capsule as a verified product offer or treating an advertised support feature as a personalized medical plan.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Fountain: Hormone therapy for womenProvider clinical service and kit; full four-, twelve- and forty-eight-week billing periods retained, exact capsule unconfirmed · Checked 2026-09-29
- Fountain: Terms and conditionsProvider terms dated April 3, 2024; medical-group, prescription and pharmacy-choice clauses, not individual coverage or refund confirmation · Checked 2026-09-29
- FDA: Understanding the Risks of Compounded DrugsFederal primary guidance on compounding and lack of FDA premarket approval; not individual treatment advice · Checked 2026-09-29
- FDA: Prometrium progesterone capsules prescribing informationExact FDA product label, reference ID 5744934; ingredients, indications and warnings apply to this product, not all progesterone preparations · Checked 2026-09-29